SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB

[X]  Quarterly  report under Section 13 or 15(d) of the Securities  Exchange Act
     of 1934 for the quarterly period ended September  30, 2004.

[ ]  Transition report under Section 13 or 15(d) of the Securities  Exchange Act
     of 1934 for the transition period from ______________ to ______________

                       Commission file number: 000-32757

                            A J&J PHARMA CORPORATION.
                     --------------------------------------
        (Exact name of small business issuer as specified in its charter)



           NEVADA                                               86-1024853
--------------------------------------------------------------------------------
(State or other jurisdiction of                               (I.R.S. Employer
incorporation or organization)                               Identification No.)

               8776 East Shea, Suite B3A323, Scottsdale, AZ 85260
                   ------------------------------------------
               (Address of principal executive office) (Zip Code)

                                  602-821-6492
                              ---------------------
                           (Issuer's telephone number)


Check whether the issuer:  (1) filed all reports required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days.

Yes XX  No
   ----    ----

The number of outstanding shares of the issuer's common stock, $0.001 par value,
as of September 30, 2004 was 1,000,000.


                                       1
<PAGE>


                            A J&J PHARMA CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)


                                TABLE OF CONTENTS


PPart I    Financial Information

  Item 1. Financial Statements:

          Condensed Balance Sheets
          September 30, 2004 (unaudited) and December 31, 2003.................3

          Unaudited Condensed Statements of Operations for the
          three and nine months ended September 30, 2004 and 2003,
          and cummulative from inception on July 16,1998 through
          September 30, 2004 ..................................................4

          Unaudited Condensed Statements of Cash Flows for the
          nine months ended September 30, 2004 and 2003, and cummulative
          from inception on July 16,1998 through September 30, 2004............5

          Statement of Stockholders' equity for the period from
          July 16,1998 to September 30, 2004 (unaudited).......................6

          Notes to Financial Statements (unaudited)............................7

  Item 2. Plan of operation

  Item 2. Plan of operation....................................................7

Part II   Other Information

  Item 1. Legal Proceedings....................................................7

  Item 2. Change in Securities.................................................7

  Item 6. Exhibits and Reports on Form 8-K ....................................7

  Signatures...................................................................8


                                       2
<PAGE>


Part I Financial Information

Item 1. Financial Statements


                            A J&J PHARMA CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
                            CONDENSED BALANCE SHEETS




                                                 September 30,    December 31,
                                                     2004            2003
                                                 -------------  ---------------
                                                  (unaudited)
                       ASSETS
                    ------------

 ASSETS                                              $       -        $       -
                                                 =============  ===============

                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)


CURRENT LIABILITIES

       Accounts payable, Officers                    $  25,067       $   19,933
                                                 -------------  ---------------
       Total Current Liabilities                        25,067           19,933
                                                 -------------  ---------------
COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY (DEFICIT)

Common stock, par value $.001, 25,000,000
  shares authorized, 1,000,000 issued and
  outstanding                                            1,000            1,000
Paid in capital                                          1,800            1,800
( Deficit) accumulated during the development stage    (27,867)         (22,733)
                                                 -------------  ---------------
Total Stockholders' Equity (Deficit)                   (25,067)         (19,933)
                                                 -------------  ---------------
                                                     $       -        $       -
                                                 =============  ===============



                 SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS

                                       3
<PAGE>

                            A J&J PHARMA CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
                       CONDENSED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                       Cummulative
                                                                                           from
                                                                                         July 16,
                                                                                           1998
                                    Three Months Ended         Nine Months Ended       (Inception)
                                       September 30,             September 30,              to
                                  --------------------------------------------------   September 30,
                                      2004        2003         2004         2003            2004
                                  ------------------------  ------------------------  ---------------
<S>                                     <C>        <C>           <C>          <C>            <C>
REVENUES                          $         -  $         -   $        -  $         -  $             -
                                  -----------  -----------  -----------  -----------  ---------------
EXPENSES
   General and administrative           1,416        1,285        5,134        3,320           27,867
                                  -----------  -----------  -----------  -----------  ---------------
   Total expenses                       1,416        1,285        5,134        3,320           27,867
                                  -----------  -----------  -----------  -----------  ---------------
NET (LOSS)                        $    (1,416) $    (1,285) $    (5,134) $    (3,320) $       (27,867)
                                  ===========  ===========  ===========  ===========  ===============
NET (LOSS) PER SHARE                    *           *            *             *
                                  ===========  ===========  ===========  ===========

WEIGHTED AVERAGE NUMBER OF
  COMMON SHARES OUTSTANDING         1,000,000    1,000,000    1,000,000    1,000,000
                                  ===========  ===========  ===========  ===========

*  less than $.01 per share


</TABLE>



                 SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS


                                       4
<PAGE>

                            A J&J PHARMA CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
                       CONDENSED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<table>
<caption>

                                                                            Cumulative
                                                                              from
                                                                             July 16,
                                                    Nine  Months Ended        1998
                                                     September 30,         (Inception)
                                               -------------------------        to
                                                   2004         2003      September 30, 2004
                                               ------------ ------------ -------------------
<S>                                                <C>           <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES

OPERATING ACTIVITIES
         Net (loss) from operations             $    (5,134) $     (3,320) $       (27,867)
                                               ------------ ------------- ----------------

NET CASH (USED BY) OPERATING ACTIVITIES              (5,134)       (3,320)         (27,867)
                                               ------------ ------------- ----------------
FINANCING ACTIVITIES
         Shareholder advances                         5,134         3,320           25,067
         Proceeds from sale of common stock                                          2,800
                                               ------------ ------------- ----------------
NET CASH PROVIDED BY FINANCING ACTIVITIES             5,134         3,320           27,867
                                               ------------ ------------- ----------------
NET INCREASE IN CASH                                      -             -                -

CASH, BEGINNING OF PERIOD                                 -
                                               ------------ ------------- ----------------
CASH, END OF PERIOD                             $         -  $          -  $             -
                                               ============ ============= ================
</table>


                 SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS





                                       5
<PAGE>

                            A J&J PHARMA CORPORATION
                         ( a Development Stage Company)
                       STATEMENTS OF STOCKHOLDERS' EQUITY
                                    (DEFICIT)

<TABLE>
<CAPTION>

                                                                   (Deficit)
                                                                   Accumulated
                                     Common Stock                   During the
                                 --------------------   Paid-in    Development
                                   Shares    Amount     Capital      Stage          Total
                                 --------------------  ----------  -----------    ---------

<S>                                <C>          <C>        <C>          <C>           <C>
Balances, at inception                    -  $      -  $      -   $          -   $      -
July 16, 1998:
Proceeds from sale of common
  stock at $.01 per share           200,000      200      1,800                      2,000
Proceeds from sale of common

  stock at par value $.001          800,000      800                                   800
  Net (loss) for the period                                            (2,385)      (2,385)
                                 ----------------------------------------------------------

Balances, December 31, 1998       1,000,000    1,000      1,800        (2,385)         415
  Net (loss) for the year                                              (2,985)      (2,985)
                                 ----------------------------------------------------------
Balances, December 31, 1999       1,000,000    1,000      1,800        (5,370)      (2,570)
  Net (loss) for the year                                              (2,985)      (2,985)
                                 ---------------------------------------------------------

Balances, December 31, 2000       1,000,000    1,000      1,800        (8,355)      (5,555)
  Net (loss) for the year                                              (5,685)      (5,685)
                                 ----------------------------------------------------------

Balances, December 31, 2001       1,000,000    1,000      1,800       (14,040)     (11,240)
  Net (loss) for the year                                              (4,335)      (4,335)
                                 ----------------------------------------------------------

Balances, December 31, 2002       1,000,000    1,000      1,800       (18,375)     (15,575)
  Net (loss) for the year                                              (4,358)      (4,358)
                                 ----------------------------------------------------------

Balances, December 31, 2003       1,000,000    1,000      1,800       (22,733)     (19,933)
(unaudited)                      ----------------------------------------------------------
  Net (loss) for the nine
   months ended September 30, 2004                                     (5,134)      (5,134)
                                 ----------------------------------------------------------

Balances, September 30, 2004      1,000,000  $ 1,000   $ 1,800    $   (27,867)   $ (25,067)
                                 ==========================================================

</TABLE>

                 SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS

                                       6
<PAGE>



                            A J&J PHARMA CORPORATION

Notes to Financial Statements (unaudited)

Note 1. BASIS OF PRESENTATION

In the opinion of management,  the accompanying  unaudited  condensed  financial
statements have been prepared in accordance with generally  accepted  accounting
principles for interim  financial  information and with the instructions to Form
10-QSB.  Accordingly,  they do not include all of the  information and footnotes
required by generally  accepted  accounting  principles  for complete  financial
statements. In the opinion of management,  all adjustments (consisting of normal
recurring  accruals)  considered  necessary  for  a  fair  presentation  of  the
Company's  financial  position as of  September  30, 2004 and the results of its
operations  for the three and nine months ended  September 30, 2004 and 2003 and
cash flows for the nine months ended September 30, 2004 and 2003 have been made.
Operating  results  for  the  nine  months  ended  September  30,  2004  are not
necessarily  indicative  of the results  that may be expected for the year ended
December 31, 2004.

These  condensed  financial  statements  should be read in conjunction  with the
financial  statements  and notes thereto  contained in the Company's Form 10-KSB
for the year ended December 31, 2003.


ITEM 2. PLAN OF OPERATION

For the near term,  the  Company  continues  to seek merger  and/or  acquisition
candidates.  It has had no substantially  earned revenues since inception and is
financially  dependent on its  shareholders,  who have financed its existence to
date.  Management of the Company believes that its shareholders will continue to
provide the finances the Company requires,  without the need to raise additional
capital.



PART II - OTHER INFORMATION

Item 1. Legal Proceedings
        None

Item 2. Changes in Securities
        None

Item 6. Exhibits and Reports on Form 8-K

     (a) Exhibits

     31.1 Certificate of CEO as Required by Rule 13a-14(a)/15d-14

     31.2 Certificate of CFO as Required by Rule 13a-14(a)/15d-14

     32.1 Certificate  of CEO as Required by Rule  13a-14(b) and Rule  15d-14(b)
          (17 CFR  240.15d-14(b))  and Section 1350 of Chapter 63 of Title 18 of
          the United States Code

     32.1 Certificate  of CFO as Required by Rule  13a-14(b) and Rule  15d-14(b)
          (17 CFR  240.15d-14(b))  and Section 1350 of Chapter 63 of Title 18 of
          the United States Code

     (b) Reports on Form 8-K
         None

                                       7
<PAGE>

SIGNATURE

     In accordance  with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this registration  statement to be signed on its behalf by the
undersigned, thereto duly authorized.


A J&J PHARMA CORPORATION
(Registrant)

Date: September 30, 2004
By:/s/Kevin Ericksteen
----------------------------
Kevin Ericksteen
President and Director

                                       8
<PAGE>

                                  EXHIBIT 31.1
                                  CERTIFICATION

I, Kevin Ericksteen, certify that:

1. I have  reviewed  this  quarterly  report  on  Form  10-QSB  of A J&J  PHARMA
CORPORATION;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
registrant's   board  of  directors  (or  persons   performing   the  equivalent
functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date:September 30, 2004
/s/ Kevin Ericksteen
------------------------
By: Kevin Ericksteen, CEO

                                       9
<PAGE>

                                  EXHIBIT 31.2
                                  CERTIFICATION

I, Kevin Ericksteen, certify that:

1. I have  reviewed  this  quarterly  report  on  Form  10-QSB  of A J&J  PHARMA
CORPORATION.;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
registrant's   board  of  directors  (or  persons   performing   the  equivalent
functions):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: September 30, 2004
/s/ Kevin Ericksteen
-------------------------
By: Kevin Ericksteen, CFO

                                       10
<PAGE>


                                  EXHIBIT 32.1
                            CERTIFICATION PURSUANT TO
                                 18 U.S.C. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In  connection  with the  Quarterly  Report  of A J&J  PHARMA  CORPORATION  (the
"Company") on Form 10-QSB for the period ended September 30, 2004, as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
Kevin Ericksteen,  Chief Financial Officer of the Company,  certify, pursuant to
18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

The  information  contained  in the  Report  fairly  presents,  in all  material
respects, the financial condition and results of operations of the Company.


                                                  /s/ Kevin Ericksteen
                                                  ---------------------------
Date: September 30, 2004                              Kevin Ericksteen
                                                      Chief Financial Officer

                                       11
<PAGE>



                                  EXHIBIT 32.2
                            CERTIFICATION PURSUANT TO
                                 18 U.S.C. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In  connection  with the  Quarterly  Report  of A J&J  PHARMA  CORPORATION  (the
"Company") on Form 10-QSB for the period ended September 30, 2004. as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
Kevin Ericksteen,  Chief Executive Officer of the Company,  certify, pursuant to
18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

The  information  contained  in the  Report  fairly  presents,  in all  material
respects, the financial condition and results of operations of the Company.


                                                   /s/ Kevin Ericksteen
                                                   --------------------------
Date: September 30, 2004                               Kevin Ericksteen
                                                       Chief Executive Officer

                                       12
<PAGE>